Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Non-Hodgkin Lymphoma through trial conditions or approval indications mapped to it or to one of its descendant entities.
45 drugs · 284 active trials
27 drugs · 479 active trials
56 drugs · 2,316 active trials
Outside the funnel: Phase not stated 1 · Withdrawn 1. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 19 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Imiquimod | Phase 1 | Early Phase 1 | 1 | 1 | 0 | 2 | 0 | — | — | 2020-04 |
| Roflumilast | Phase 1 | Phase 1 | 1 | 1 | 0 | 1 | 0 | — | — | Jun 20, 2025 |
| Ropeginterferon Alfa-2b | Phase 1 | Phase 1 | 1 | 1 | 0 | 1 | 0 | — | — | Aug 27, 2025 |
| Hydroxychloroquine | Phase 1 | Phase 1 | 0 | 0 | 0 | 3 | 0 | — | — | 2011-06 |
| Alvespimycin | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | 2004-07 |
| Apitolisib | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | 2009-03 |
| Fulvestrant | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | Mar 16, 2011 |
| Letrozole | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | Mar 16, 2011 |
| Ridaforolimus | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | 2003-04 |
| Volasertib | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | 2016-10 |
| Abiraterone | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Alpelisib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Jul 23, 2014 |
| Aminolevulinic Acid | Phase 1 | Early Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Nov 13, 2017 |
| Bicalutamide | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Birabresib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | May 19, 2016 |
| Bone Marrow Transplantation | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2011-08 |
| Cabazitaxel | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Cediranib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2007-05 |
| Conatumumab | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2008-02 |
| Darolutamide | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Dovitinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2013-02 |
| Elimusertib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Jul 6, 2017 |
| Entrectinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| FOLFIRI Regimen | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Sep 23, 2020 |
| Ganetespib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2012-01 |
| HDAC Inhibitor REC-2282 | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | May 4, 2010 |
| HyperCVAD Regimen | Phase 1 | Early Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2010-07 |
| Ibuprofen | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Nov 18, 2020 |
| Immunotherapy | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2007-03 |
| Lenvatinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Mcl-1 Inhibitor MIK665 | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Jun 23, 2021 |
| Mocetinostat | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2004-04 |
| Molibresib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Sep 18, 2020 |
| MUC1-targeted Peptide GO-203-2C | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | — |
| Neratinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Niacinamide | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2008-06 |
| Nilotinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2010-08 |
| Niraparib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2008-09 |
| Pictilisib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2008-03 |
| Ramucirumab | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Oct 21, 2016 |
| Regorafenib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Retaspimycin Hydrochloride | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2005-06 |
| Trabectedin | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Jun 18, 2019 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.